• Dan-Jie Zhao, Ling-Mei Huang, Jie Xiao, Long Chen, Xia Li, and Hai-Xia Lin.
• Department of Pharmacology, The First People's Hospital of Shuangliu District, West China (Airport) Hospital of Sichuan University, Chengdu, China.
• Medicine (Baltimore). 2023 Aug 4; 102 (31): e34516e34516.

BackgroundTo assess the efficacy and safety of Tralokinumab in the treatment of moderate-to-severe atopic dermatitis (AD).MethodsPubMed, Embase, Clinical Trials Website, and Cochrane Library were systematically searched for eligible randomized controlled trials which assessed the effects of Tralokinumab on AD. Primary outcomes included Scoring Atopic Dermatitis score, EASI-75%, and Investigator's Global Assessment score of 0 or 1 in 12 to 16 weeks. Secondary outcomes included the Eczema area and severity index score, the Numeric Rating Scales score, the dermatology life quality index score, and the overall incidence of adverse events. The quality of included studies was evaluated using the Cochrane System and the modified Jadad scale. Analysis was performed using Stata 16 software.ResultsEight randomized controlled trials involving 2878 patients were included in this meta-analysis. Compared to placebo, Tralokinumab treatment exhibited a significantly higher Scoring Atopic Dermatitis score [SMD = -0.53, 95% confidence intervals [CI]: -0.62 to -0.44, P < .00001], an increased number of patients with EASI-75% [odds ratio (OR) = 2.44, 95% CI: 2.00-2.97, P < .00001] and Investigator's Global Assessment score of 0 or 1 in 12 to 16 weeks [OR = 2.12, 95% CI: 1.71-2.63, P < .00001]. No significant difference was observed in the incidence of overall adverse events [OR = 1.00, 95% CI: 0.85-1.18, P = 1.00] between the 2 groups.ConclusionTralokinumab is effective and safe in treatment of moderate-to-severe AD.Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.

11 keywords...

hide…